© 2003 by European Society of Cardiology
Copyright © 2003, European Society of Cardiology
Endothelial progenitor cell culture and differentiation in vitro: a methodological comparison using human umbilical cord blood
aDepartment of Internal Medicine II (Cardiology), Ulm University Medical Centre, Robert-Koch-Str. 8, D-89081 Ulm, Germany
bUniversity Children's Hospital, Ulm University Medical Centre, 89081 Ulm, Germany
johannes.waltenberger{at}medizin.uni-ulm.de
* Corresponding author. Tel.: +49-731-500-24464; fax: +49-731-500-24533.
Objective: Endothelial progenitor cells (EPC) can contribute to vascular repair and targeted tumour therapy. Little is known about generating EPC from human umbilical cord blood. We therefore compared methods for purification of EPC from human umbilical cord blood. Methods: Mononuclear cells were isolated from human umbilical cord blood by density gradient centrifugation and used either unselected or after CD34 preselection. Unselected mononuclear cells were cultured for 9 days. Culture-dish-adherent (CDAC) and non-adherent (CDNAC) CD34+ cells were cultured separately for 4 weeks. Surface markers were assessed by immunofluorescence staining and FACS analysis. Results: In unselected mononuclear cells, VEGF-R2 and VE-cadherin expression increased up to day 6. They stained positive with UEA-1 and took up acetylated LDL. Expression of CD45 and CD14 decreased over time, but remained strong. CD133 and CD34 were not expressed. CD34+-CDNAC acquired an endothelial phenotype over time with an increase of VEGFR-2 and von Willebrand factor (vWF). CD45 and CD14 decreased, while CD34 and the progenitor-cell marker CD133 remained strongly expressed. CD34+-CDAC showed a strong increase in VEGFR-2, CD133, CD34 and vWF, while CD14 decreased, and CD45 did not change. Conclusion: Putative EPC can be obtained from human umbilical cord blood. When selected for CD34, cells can be differentiated in culture to express markers of mature endothelial cells, while keeping progenitor markers. In contrast, short-term culture of unselected mononuclear cells leads to an endothelioid–monocytoid phenotype devoid of progenitor markers. Thus, the outgrowth from CD34-selected cells appears to be superior to short-term culture of unselected mononuclear cells with regard to endothelial cell-lineage specific differentiation of cells with a progenitor marker profile.
KEYWORDS Ac LDL, acetylated low density lipoprotein; bFGF, basic fibroblast growth factor; DiI, 1,1'-dioctadecyl-3,3,3'3'-tetramethylindocarbocyanine perchlorate; EC, endothelial cells; ECGF, endothelial cell growth supplement; EPC, endothelial progenitor cells; HUCB, human umbilical cord blood; LDL, low density lipoprotein; mAb, monoclonal antibody; MNC, mononuclear cells; NO, nitric oxide; CDAC, culture-dish-adherent cells; PBS, phosphate buffered saline; CDNAC, culture-dish-non-adherent cells; VEGF, vascular endothelial growth factor; VEGFR-2, vascular endothelial growth factor receptor-2; vWF, von Willebrand factor
1 Present address: Institute of Immunology, University of Magdeburg, Magdeburg, Germany.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  B. Hibbert, X. Ma, A. Pourdjabbar, E. Holm, K. Rayner, Y.-X. Chen, J. Sun, L. Filion, and E. R. O'Brien Inhibition of endothelial progenitor cell glycogen synthase kinase-3{beta} results in attenuated neointima formation and enhanced re-endothelialization after arterial injury Cardiovasc Res, July 1, 2009; 83(1): 16 - 23. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Yamahara and H. Itoh Potential use of endothelial progenitor cells for regeneration of the vasculature Therapeutic Advances in Cardiovascular Disease, February 1, 2009; 3(1): 17 - 27. [Abstract] [PDF]
|
|
|
|
 |
|
 K. C. Partlow, J. Chen, J. A. Brant, A. M. Neubauer, T. E. Meyerrose, M. H. Creer, J. A. Nolta, S. D. Caruthers, G. M. Lanza, and S. A. Wickline 19F magnetic resonance imaging for stem/progenitor cell tracking with multiple unique perfluorocarbon nanobeacons FASEB J, June 1, 2007; 21(8): 1647 - 1654. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. C. Schatteman, M. Dunnwald, and C. Jiao Biology of bone marrow-derived endothelial cell precursors Am J Physiol Heart Circ Physiol, January 1, 2007; 292(1): H1 - H18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Ma, Y. Ladilov, J. M. Moebius, L. Ong, C. Piechaczek, A. David, A. Kaminski, Y.-H. Choi, W. Li, D. Egger, et al. Intramyocardial delivery of human CD133+ cells in a SCID mouse cryoinjury model: Bone marrow vs. cord blood-derived cells Cardiovasc Res, July 1, 2006; 71(1): 158 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. Atluri, G. P. Liao, C. M. Panlilio, V. M. Hsu, M. J. Leskowitz, K. J. Morine, J. E. Cohen, M. F. Berry, E. E. Suarez, D. A. Murphy, et al. Neovasculogenic therapy to augment perfusion and preserve viability in ischemic cardiomyopathy. Ann. Thorac. Surg., May 1, 2006; 81(5): 1728 - 1736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Post and J. Waltenberger ACE inhibitors and statins for bone marrow failure following myocardial infarction? Cardiovasc Res, April 1, 2006; 70(1): 1 - 2. [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Ingram, N. M. Caplice, and M. C. Yoder Unresolved questions, changing definitions, and novel paradigms for defining endothelial progenitor cells Blood, September 1, 2005; 106(5): 1525 - 1531. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
X. Wu, E. Rabkin-Aikawa, K. J. Guleserian, T. E. Perry, Y. Masuda, F. W. H. Sutherland, F. J. Schoen, J. E. Mayer Jr., and J. Bischoff Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells Am J Physiol Heart Circ Physiol, August 1, 2004; 287(2): H480 - H487. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Herder, T. Tonn, R. Oostendorp, S. Becker, U. Keller, C. Peschel, M. Grez, and E. Seifried Sustained Expansion and Transgene Expression of Coagulation Factor VIII-Transduced Cord Blood-Derived Endothelial Progenitor Cells Arterioscler Thromb Vasc Biol, December 1, 2003; 23(12): 2266 - 2272. [Abstract] [Full Text] [PDF]
|
|